Published in Trop Med Int Health on June 01, 2007
Genetic diversity of Mycobacterium tuberculosis isolates from a tertiary care tuberculosis hospital in South Korea. J Clin Microbiol (2009) 1.49
How host heterogeneity governs tuberculosis reinfection? Proc Biol Sci (2012) 1.08
Interferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis. J Infect Dis (2010) 1.00
Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol (2006) 11.86
Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet (2009) 7.22
Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis (2007) 6.41
Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med (2010) 5.01
Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet (2006) 4.73
Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2002) 4.10
Mycobacterium ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997-2001. Emerg Infect Dis (2004) 3.08
Molecular evidence to support a proposal to reserve the designation Mycobacterium avium subsp. avium for bird-type isolates and 'M. avium subsp. hominissuis' for the human/porcine type of M. avium. Int J Syst Evol Microbiol (2002) 3.02
Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol (2013) 2.89
Mycobacterium ulcerans infection: control, diagnosis, and treatment. Lancet Infect Dis (2006) 2.73
Mycobacterium ulcerans disease. Bull World Health Organ (2005) 2.30
Buruli ulcer disease in Cameroon rediscovered. Am J Trop Med Hyg (2004) 2.29
Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia. Respir Res (2006) 2.15
Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis (2003) 2.11
Evolution of Mycobacterium ulcerans and other mycolactone-producing mycobacteria from a common Mycobacterium marinum progenitor. J Bacteriol (2006) 2.10
Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect Immun (2003) 2.08
Psychosocial aspects of health seeking behaviours of patients with Buruli ulcer in southern Benin. Trop Med Int Health (2003) 2.07
Genotyping Mycobacterium ulcerans and Mycobacterium marinum by using mycobacterial interspersed repetitive units. J Bacteriol (2005) 2.06
Genotypic and phenotypic heterogeneity among Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients. J Clin Microbiol (2004) 2.06
Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol (2013) 1.99
Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method. Antimicrob Agents Chemother (2003) 1.93
First cultivation and characterization of Mycobacterium ulcerans from the environment. PLoS Negl Trop Dis (2008) 1.93
Risk factors for buruli ulcer: a case control study in Cameroon. PLoS Negl Trop Dis (2007) 1.90
Buruli ulcer (Mycobacterium ulcerans infection). Trans R Soc Trop Med Hyg (2008) 1.88
Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis. PLoS One (2009) 1.87
Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother (2009) 1.82
Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother (2006) 1.80
Mycobacteria in drinking water distribution systems: ecology and significance for human health. FEMS Microbiol Rev (2005) 1.79
Primary culture of Mycobacterium ulcerans from human tissue specimens after storage in semisolid transport medium. J Clin Microbiol (2007) 1.79
Multilocus variable-number tandem repeat typing of Mycobacterium ulcerans. J Clin Microbiol (2005) 1.77
The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother (2008) 1.71
High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother (2009) 1.69
Buruli ulcer recurrence, Benin. Emerg Infect Dis (2005) 1.69
Optimal tuberculosis case detection by direct sputum smear microscopy: how much better is more? Int J Tuberc Lung Dis (2002) 1.67
One-tube cell lysis and DNA extraction procedure for PCR-based detection of Mycobacterium ulcerans in aquatic insects, molluscs and fish. J Med Microbiol (2004) 1.59
Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun (2005) 1.59
On the origin of Mycobacterium ulcerans, the causative agent of Buruli ulcer. BMC Genomics (2012) 1.58
Potential role for fish in transmission of Mycobacterium ulcerans disease (Buruli ulcer): an environmental study. Appl Environ Microbiol (2004) 1.57
Comparative evaluation of the nitrate reduction assay, the MTT test, and the resazurin microtitre assay for drug susceptibility testing of clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother (2005) 1.53
Buruli ulcer distribution in Benin. Emerg Infect Dis (2005) 1.52
Rapid alternative methods for detection of rifampicin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother (2004) 1.51
Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease). PLoS Negl Trop Dis (2010) 1.48
Newly developed primers for comprehensive amplification of the rpoB gene and detection of rifampin resistance in Mycobacterium tuberculosis. J Clin Microbiol (2006) 1.45
Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun (2006) 1.45
Genetic diversity in Mycobacterium ulcerans isolates from Ghana revealed by a newly identified locus containing a variable number of tandem repeats. J Bacteriol (2006) 1.44
Mycobacterium ulcerans disease (Buruli ulcer) in a rural hospital in Bas-Congo, Democratic Republic of Congo, 2002-2004. Am J Trop Med Hyg (2006) 1.42
Buruli ulcer: Advances in understanding Mycobacterium ulcerans infection. Dermatol Clin (2011) 1.37
Fine-needle aspiration, an efficient sampling technique for bacteriological diagnosis of nonulcerative Buruli ulcer. J Clin Microbiol (2009) 1.34
Direct detection of Mycobacterium tuberculosis complex DNA and rifampin resistance in clinical specimens from tuberculosis patients by line probe assay. J Clin Microbiol (2006) 1.34
Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet Infect Dis (2009) 1.27
Can molecular methods detect 1% isoniazid resistance in Mycobacterium tuberculosis? J Clin Microbiol (2013) 1.25
Buruli ulcer surveillance, Benin, 2003-2005. Emerg Infect Dis (2007) 1.20
Newly developed primers for the detection of Mycobacterium avium subspecies paratuberculosis. Vet Microbiol (2004) 1.19
PCR amplification with primers based on IS2404 and GC-rich repeated sequence reveals polymorphism in Mycobacterium ulcerans. J Clin Microbiol (2005) 1.19
The use of microbead-based spoligotyping for Mycobacterium tuberculosis complex to evaluate the quality of the conventional method: providing guidelines for Quality Assurance when working on membranes. BMC Infect Dis (2011) 1.18
Rifampin heteroresistance in Mycobacterium tuberculosis cultures as detected by phenotypic and genotypic drug susceptibility test methods. J Clin Microbiol (2013) 1.16
Family relationship, water contact and occurrence of Buruli ulcer in Benin. PLoS Negl Trop Dis (2010) 1.16
Buruli ulcer: a systemic disease. Clin Infect Dis (2003) 1.16
Ongoing genome reduction in Mycobacterium ulcerans. Emerg Infect Dis (2007) 1.16
A comparison of DNA extraction procedures for the detection of Mycobacterium ulcerans, the causative agent of Buruli ulcer, in clinical and environmental specimens. J Microbiol Methods (2008) 1.16
A pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis (2002) 1.14
Heterogeneity among Mycobacterium ulcerans isolates from Africa. Emerg Infect Dis (2006) 1.13
Comparative nucleotide sequence analysis of polymorphic variable-number tandem-repeat Loci in Mycobacterium ulcerans. J Clin Microbiol (2005) 1.13
Terrestrial small mammals as reservoirs of Mycobacterium ulcerans in benin. Appl Environ Microbiol (2010) 1.13
Aquatic insects and Mycobacterium ulcerans: an association relevant to Buruli ulcer control? PLoS Med (2007) 1.11
A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J Antimicrob Chemother (2006) 1.11
Buruli ulcer: a review of in vitro tests to screen natural products for activity against Mycobacterium ulcerans. Planta Med (2011) 1.10
Association of HIV infection and Mycobacterium ulcerans disease in Benin. AIDS (2008) 1.08
African 2, a clonal complex of Mycobacterium bovis epidemiologically important in East Africa. J Bacteriol (2010) 1.08
ESAT-6 and CFP-10 in clinical versus environmental isolates of Mycobacterium kansasii. J Infect Dis (2005) 1.08
Tuberculosis drug resistance testing by molecular methods: opportunities and challenges in resource limited settings. J Microbiol Methods (2010) 1.07
VNTR analysis differentiates Mycobacterium ulcerans and IS2404 positive mycobacteria. Syst Appl Microbiol (2007) 1.07
Environmental and health-related risk factors for Mycobacterium ulcerans disease (Buruli ulcer) in Benin. Am J Trop Med Hyg (2007) 1.07
Mycobacterium ulcerans disease, Peru. Emerg Infect Dis (2008) 1.07
Application of real-time PCR in Ghana, a Buruli ulcer-endemic country, confirms the presence of Mycobacterium ulcerans in the environment. FEMS Microbiol Lett (2010) 1.06
New foci of Buruli ulcer, Angola and Democratic Republic of Congo. Emerg Infect Dis (2008) 1.06
BCG vaccine effectiveness against Buruli ulcer: a case-control study in Benin. Am J Trop Med Hyg (2006) 1.06
Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol (2009) 1.05
Rapid and inexpensive detection of multidrug-resistant Mycobacterium tuberculosis with the nitrate reductase assay using liquid medium and direct application to sputum samples. J Clin Microbiol (2008) 1.05
Buruli ulcer, Nigeria. Emerg Infect Dis (2007) 1.05